Congratulations to our dear colleague Dr. John Harris, who received Presidential Early Career Award for Scientists and Engineers for his outstanding contributions to vitiligo research.
This award is the highest honor presented by the United States Government to brilliant scientists and engineers beginning their independent research careers and who show incredible promise for leadership in science and technology.
Dr. Harris is an Associate Professor at the University of Massachusetts Medical School (UMMS) in Worcester, MA. He also directs the Vitiligo Clinic and Research Center at UMMS.
John Harris is one of the top vitiligo researchers, who aims to revolutionize vitiligo treatment with a new family of drugs. These drugs inhibit downstream signaling in the interferon gamma pathway and have potential to reverse vtiligo effect on the skin. At the World Dermatology Congress in Milan this June, Dr. Harris reported promising results of Incyte's Phase II clinical trials for topical ruxolitinib, a selective JAK inhibitor. If all goes well in the Phase III trails scheduled for late 2019, this compound could be the first FDA-approved medical treatment to reverse vitiligo. More on this in our recent newsletter.
"We are very proud that Dr. Harris, a talented researcher, physician, and 2019 ASA Calder Research Scholar Award in Vitiligo and Pigment Cell Disorders recipient, has been recognized by our country with such an outstanding honor," said Howard P. Milstein, Chairman of the American Skin Association in the media release.
- Which diseases most commonly accompany vitiligo?
According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...
- What causes vitiligo?
Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...
- Will it spread?
Vitiligo activity may vary considerably from person to person. The natural course of vitiligo is truly unpredictable but usually progressive. The most recent VALIANT study on v...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.